Bionano Financial Statements From 2010 to 2025

BNGO Stock

USD 3.29 0.18 5.19%

Bionano Genomics financial statements provide useful quarterly and yearly information to potential Bionano Genomics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bionano Genomics financial statements helps investors assess Bionano Genomics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bionano Genomics' valuation are summarized below:

Gross Profit

-599 K

Market Capitalization

9.5 M

Enterprise Value Revenue

0.2695

Revenue

33.3 M

Earnings Share

(138.00)

We have found one hundred twenty available fundamental signals for Bionano Genomics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Bionano Genomics' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road.

Bionano Genomics Total Revenue

43.61 Million

Check Bionano Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bionano Genomics' main balance sheet or income statement drivers, such as Tax Provision of 58.6 K, Interest Income of 4 M or Depreciation And Amortization of 16.6 M, as well as many indicators such as Price To Sales Ratio of 91.68, Dividend Yield of 0.0 or PTB Ratio of 34.43. Bionano financial statements analysis is a perfect complement when working with Bionano Genomics Valuation or Volatility modules.

Check out the analysis of Bionano Genomics Correlation against competitors.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Bionano Genomics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

142.9 M

246.6 M

94.9 M

Slightly volatile

Short and Long Term Debt Total

95.9 M

91.3 M

25.5 M

Slightly volatile

Other Current Liabilities

9.4 M

18.8 M

8.9 M

Slightly volatile

Total Current Liabilities

120.8 M

115 M

32.2 M

Slightly volatile

Other Liabilities

15.8 M

15.1 M

4.8 M

Slightly volatile

Property Plant And Equipment Net

39.2 M

37.4 M

12.4 M

Slightly volatile

Current Deferred Revenue

555.6 K

900.5 K

511.1 K

Slightly volatile

Accounts Payable

12.5 M

11.9 M

4.5 M

Slightly volatile

Cash

17.3 M

20.6 M

12.2 M

Slightly volatile

Non Current Assets Total

48.6 M

85.4 M

32 M

Slightly volatile

Long Term Debt

11.5 M

18.8 M

10.8 M

Slightly volatile

Cash And Short Term Investments

74.8 M

117.2 M

48 M

Slightly volatile

Net Receivables

5.6 M

11.1 M

4.3 M

Slightly volatile

Common Stock Total Equity

36.2 K

34.5 K

11.5 K

Slightly volatile

Common Stock Shares Outstanding

41.2 M

39.3 M

11.7 M

Slightly volatile

Long Term Debt Total

11.5 M

18.8 M

10.8 M

Slightly volatile

Liabilities And Stockholders Equity

142.9 M

246.6 M

94.9 M

Slightly volatile

Non Current Liabilities Total

16.2 M

16.4 M

24.4 M

Slightly volatile

Capital Surpluse

723.5 M

689.1 M

222.6 M

Slightly volatile

Inventory

27.6 M

26.3 M

8.8 M

Slightly volatile

Other Current Assets

6.9 M

6.5 M

2.6 M

Slightly volatile

Total Liabilities

142.8 M

136 M

57.3 M

Slightly volatile

Property Plant And Equipment Gross

62.3 M

59.3 M

15.8 M

Slightly volatile

Short and Long Term Debt

84.3 M

80.3 M

30.9 M

Slightly volatile

Preferred Stock Total Equity

37.6 M

49.5 M

35.4 M

Slightly volatile

Total Current Assets

94.3 M

161.1 M

62.9 M

Slightly volatile

Non Current Liabilities Other

8.4 M

12.5 M

6.1 M

Slightly volatile

Short Term Debt

87.2 M

83.1 M

20.1 M

Slightly volatile

Common Stock

5.5 K

5.8 K

6.2 K

Slightly volatile

Property Plant Equipment

21.8 M

20.7 M

8.1 M

Slightly volatile

Deferred Long Term Liabilities

137.3 K

114.3 K

229.5 K

Slightly volatile

Capital Stock

5.5 K

5.8 K

6.7 K

Slightly volatile

Other Assets

3.4 M

3.2 M

883.8 K

Slightly volatile

Intangible Assets

28.4 M

39.1 M

11.6 M

Slightly volatile

Bionano Genomics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

16.6 M

15.8 M

4.6 M

Slightly volatile

Interest Expense

6.2 M

5.9 M

1.8 M

Slightly volatile

Selling General Administrative

112.9 M

107.5 M

39.4 M

Slightly volatile

Total Revenue

43.6 M

41.5 M

15.9 M

Slightly volatile

Gross Profit

11.6 M

11 M

4.8 M

Slightly volatile

Other Operating Expenses

303.5 M

289.1 M

90.1 M

Slightly volatile

Research Development

65.2 M

62.1 M

23.4 M

Slightly volatile

Cost Of Revenue

32.1 M

30.5 M

11.1 M

Slightly volatile

Total Operating Expenses

271.5 M

258.5 M

79 M

Slightly volatile

Reconciled Depreciation

16.8 M

16 M

4.7 M

Slightly volatile

Bionano Genomics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

18.3 M

17.5 M

5.5 M

Slightly volatile

Begin Period Cash Flow

6 M

6.3 M

9.6 M

Slightly volatile

Depreciation

16.8 M

16 M

4.6 M

Slightly volatile

Other Non Cash Items

112.3 M

106.9 M

19.9 M

Slightly volatile

Capital Expenditures

1.9 M

1.6 M

Slightly volatile

Total Cash From Financing Activities

88.6 M

130.9 M

63.5 M

Slightly volatile

End Period Cash Flow

17.5 M

21.1 M

12.3 M

Slightly volatile

Issuance Of Capital Stock

92.1 M

66.4 M

51 M

Slightly volatile

Dividends Paid

1.6 M

1.8 M

2 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

91.68

96.5

410

Slightly volatile

Days Sales Outstanding

138

112

116

Pretty Stable

Average Payables

1.9 M

2.5 M

2.2 M

Slightly volatile

Stock Based Compensation To Revenue

0.22

0.38

0.1854

Slightly volatile

Capex To Depreciation

0.13

0.14

0.6906

Slightly volatile

EV To Sales

93.13

98.04

410

Slightly volatile

Inventory Turnover

1.27

1.33

2.1861

Pretty Stable

Days Of Inventory On Hand

186

283

214

Slightly volatile

Payables Turnover

3.27

2.94

3.5693

Slightly volatile

Sales General And Administrative To Revenue

1.67

1.36

1.5604

Slightly volatile

Average Inventory

1.7 M

3 M

2.3 M

Slightly volatile

Research And Ddevelopement To Revenue

1.03

1.35

1.4267

Slightly volatile

Capex To Revenue

0.0922

0.0538

0.1254

Slightly volatile

Cash Per Share

2.14

2.25

8.2491

Slightly volatile

Days Payables Outstanding

121

128

122

Slightly volatile

Income Quality

1.05

0.62

1.0475

Slightly volatile

Intangibles To Total Assets

0.18

0.14

0.1661

Slightly volatile

Current Ratio

1.2

1.26

2.5355

Slightly volatile

Receivables Turnover

2.52

3.36

3.3206

Slightly volatile

Capex Per Share

0.0541

0.0569

1.4209

Slightly volatile

Average Receivables

3 M

4.1 M

3.4 M

Slightly volatile

Revenue Per Share

1.16

1.22

9.7335

Slightly volatile

Interest Debt Per Share

2.7

2.85

10.1558

Slightly volatile

Debt To Assets

0.4

0.43

0.3979

Slightly volatile

Operating Cycle

286

371

326

Slightly volatile

Days Of Payables Outstanding

121

128

122

Slightly volatile

Ebt Per Ebit

0.81

0.97

0.9515

Slightly volatile

Quick Ratio

1.0

1.05

2.2718

Slightly volatile

Net Income Per E B T

1.09

1.15

1.0118

Slightly volatile

Cash Ratio

0.2

0.21

0.9033

Very volatile

Cash Conversion Cycle

165

243

204

Pretty Stable

Days Of Inventory Outstanding

186

283

214

Slightly volatile

Days Of Sales Outstanding

138

112

116

Pretty Stable

Free Cash Flow Operating Cash Flow Ratio

1.13

1.17

1.0531

Pretty Stable

Fixed Asset Turnover

1.21

1.28

2.1248

Very volatile

Debt Ratio

0.4

0.43

0.3979

Slightly volatile

Price Sales Ratio

91.68

96.5

410

Slightly volatile

Asset Turnover

0.36

0.19

0.373

Slightly volatile

Gross Profit Margin

0.34

0.3

0.3715

Slightly volatile

Bionano Genomics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

1.8 B

2 B

2.2 B

Slightly volatile

Enterprise Value

1.8 B

2 B

2.2 B

Slightly volatile

Bionano Fundamental Market Drivers

Cash And Short Term Investments

101.9 M

Bionano Upcoming Events

	14th of March 2024 Upcoming Quarterly Report	View
	14th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	14th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Bionano Genomics Financial Statements

Bionano Genomics investors utilize fundamental indicators, such as revenue or net income, to predict how Bionano Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	900.5 K	555.6 K
Total Revenue	41.5 M	43.6 M
Cost Of Revenue	30.5 M	32.1 M
Stock Based Compensation To Revenue	0.38	0.22
Sales General And Administrative To Revenue	1.36	1.67
Research And Ddevelopement To Revenue	1.35	1.03
Capex To Revenue	0.05	0.09
Revenue Per Share	1.22	1.16
Ebit Per Revenue	(6.85)	(7.20)

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Stock

0.82

23Andme Holding

Pair Corr

Moving against Bionano Stock

0.83	VALN	Valneva SE ADR	Pair Corr
0.72	VIGL	Vigil Neuroscience	Pair Corr
0.67	DMAC	DiaMedica Therapeutics	Pair Corr
0.63	DVAX	Dynavax Technologies	Pair Corr
0.5	VERV	Verve Therapeutics	Pair Corr

The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.

The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:

How To Invest In Bionano

Details

Is Bionano Stock a good investment?

Details

What is Bionano Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Bionano Genomics Correlation against competitors.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(138.00)

Revenue Per Share

32.507

Quarterly Revenue Growth

(0.35)

Return On Assets

(0.48)

Return On Equity

(1.62)

The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bionano Financial Statements From 2010 to 2025

Bionano Genomics Total Revenue

43.61 Million

Bionano Genomics Balance Sheet

Bionano Genomics Income Statement

Bionano Genomics Cash Flow Statement

Financial Ratios

Bionano Genomics Valuation Data

Bionano Fundamental Market Drivers

Bionano Upcoming Events

About Bionano Genomics Financial Statements

Pair Trading with Bionano Genomics

Moving together with Bionano Stock

Moving against Bionano Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY